Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Coronary artery disease

Are β-blockers truly helpful in patients with CAD?

Nature Reviews Cardiology volume 10, pages 11–12 (2013)Cite this article

Subjects

In a large, new, observational study, β-blocker treatment did not improve clinical outcomes in patients with coronary artery disease (CAD), including those with previous myocardial infarction, and was associated with more events in individuals with risk factors only. The role of β-blockers for secondary prevention in these patients should be reconsidered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effect of long-term β-blocker therapy after ST-segment elevation myocardial infarction.

References

  1. Freemantle, N., Cleland, J., Young, P., Mason, J. & Harrison, J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318, 1730–1737 (1999).

    Article  CAS  Google Scholar 

  2. Antman, E. M. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 117, 296–329 (2008).

    Article  Google Scholar 

  3. Steg, P. G. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33, 2569–2619 (2012).

    Article  CAS  Google Scholar 

  4. Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341–1381 (2006).

    Article  Google Scholar 

  5. Bangalore, S. et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308, 1340–1349 (2012).

    Article  CAS  Google Scholar 

  6. Shu, D. F., Dong, B. R., Lin, X. F., Wu, T. X. & Liu, G. J. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur. J. Prev. Cardiol. 19, 330–341 (2012).

    Article  Google Scholar 

  7. Tuppin, P. et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch. Cardiovasc. Dis. 103, 363–375 (2010).

    Article  Google Scholar 

  8. Boutouyrie, P. et al. Pharmacological modulation of arterial stiffness. Drugs 71, 1689–1701 (2011).

    Article  CAS  Google Scholar 

  9. Ong, K. T. et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers–Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376, 1476–1484 (2010).

    Article  CAS  Google Scholar 

  10. Bangalore, S., Parkar, S., Grossman, E. & Messerli, F. H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100, 1254–1262 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, 75015, France

    Nicolas Danchin

  2. Department of Pharmacology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris, 75015, France

    Stéphane Laurent

Authors
  1. Nicolas Danchin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphane Laurent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Danchin.

Ethics declarations

Competing interests

N. Danchin is or has been a consultant for the following companies: AstraZeneca, Bayer, Bristol–Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck, Novo-Nordisk, Pfizer, Roche, Sanofi-Aventis, Servier, and The Medicines Company. N. Danchin has received honoraria from the following companies: AstraZeneca, Bayer, Bristol–Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Novo-Nordisk, Sanofi-Aventis, Servier, and The Medicines Company. N. Danchin has received grant or research support from the following companies: AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier, and The Medicines Company.

S. Laurent is or has been a consultant for AstraZeneca. S. Laurent has received honoraria from the following companies: Bayer Schering, Boehringer Ingelheim, Chiesi, Daiichi Sankyo, Menarini, Negma, Novartis, Omron, Recordati, and Servier. S. Laurent has received grant or research support from the following companies: Actor, Esaote, and Servier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danchin, N., Laurent, S. Are β-blockers truly helpful in patients with CAD?. Nat Rev Cardiol 10, 11–12 (2013). https://doi.org/10.1038/nrcardio.2012.159

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.159

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing